Basics of Benzodiazepine Use Disorder. DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR
|
|
- Deirdre Barker
- 5 years ago
- Views:
Transcription
1 Basics of Benzodiazepine Use Disorder DATE: October 3, 2017 PRESENTED BY: Melissa B. Weimer, DO, MCR
2 Disclosures Speaker disclosure: One time lecture sponsored by Indivior about overlap of pain and opioid dependence without mention of medication for which I received honorarium. Planner disclosure: None 2 2
3 Objectives Understand the mechanism of action and pharmacokinetic properties of benzodiazepines Understand that differentiating between benzodiazepine physiologic dependence and benzodiazepine use disorder may be challenging Describe how to safely taper benzodiazepine therapy 3 3
4 Benzos are positive allosteric modulators Increase the GABA A receptor s affinity for GABA
5 Benzodiazepine Metabolism Glucuronide Conjugation o Shorter half-life o Inactive metabolites o Safer in liver disease and elderly Lorazepam Oxazepam Temazepam (remember LOT) Oxidation o Longer half-life o More metabolites o Use caution in liver disease Chlordiazepoxide Diazepam Clonazepam
6
7 Benzodiazepine Equivalency
8 Withdrawal Symptoms: occur after days of use
9 Features of a Benzo Use Disorder vs Benzo physiologic dependence Tolerance Withdrawal When severe, these 2 issues can cause problems with their life, ability to cope Benzo dependence alone Benzo use disorder Tolerance Withdrawal Loss of control of use Continued use despite social or interpersonal issues related to use Giving up other activities due to use No longer fulfilling major life obligations Consistent use despite acknowledgement of harms Wanting to cut down, but not being able Taking in larger amounts and longer than intended
10
11 Withdrawal Management Soyka, weeks to taper, maybe longer, but not too long 10-50% in first week Hospitalize if > 100mg diazepam equivalents Don t withdraw opioids at the same time Adjuncts: pregabalin/gabapentin, carbamazepine, SSRIs, TCAs, antihistamines, melatonin Limited evidence for AEDs, but still consider
12 Withdrawal Management Calculate benzodiazepine equivalency ( Reduce by 25-30% per day or week, depending on time course Create taper plan based on Time in detox Ability to safely assure taper and monitor patient Other risk factors like opioid use, alcohol use, etc Adjuvant meds Carbamazepine 200mg BID or Divalproic Acid 250mg TID Vistaril 25-50mg QID Buspar 5-10mg TID Trazodone for sleep Consider clonidine or prazosin
13 Case Example 1 Real case Joe is a 72 yo man with HTN and hyperlipidemia. He developed severe anxiety after retirement approximately 10 years ago and was prescribed lorazepam 1mg BID. He found it helped him at first, but now he feels like it is a crutch and he doesn t like the effect his wife says it has on him. He would like to stop the medication but every time he stops, he becomes sweaty, fearful, anorexic and can not sleep. He would like to stop the medication before he goes on a cruise in 10 days. He has been erratically taking his meds over the last 2 weeks in an attempt to stop them, but has not been able to sleep.
14 Features of a Benzo Use Disorder vs Benzo physiologic dependence Tolerance Withdrawal Benzo dependence alone Benzo use disorder Tolerance Withdrawal Loss of control of use Continued use despite social or interpersonal issues related to use Giving up other activities due to use No longer fulfilling major life obligations Consistent use despite acknowledgement of harms Wanting to cut down, but not being able Taking in larger amounts and longer than intended
15 Taper plan Enjoy your vacation on a stable dose of benzos! Start taper when you return Consider transition to clonazepam or diazepam Taper by 10-25% per week depending on how well patient tolerates the withdrawal Start mirtazapine and melatonin for sleep Refer for CBT
16 Case Example 2 Real case Joanne is a 52 year old female with hx of PTSD and major recurrent depression who seeks care in your primary care clinic for help getting off of benzos. She has been prescribed benzos (diazepam) since age 20 and has tried several times to stop them. She has developed a social phobia about psychiatrists. She can not go longer than 4 hours between doses or she has severe panic, though she does not take them more than prescribed to her Her friend recently drove to FL to pick her up because she was so distraught over her use and inability to stop. She desperately wants to stop and her friend plans to help her and support her.
17 Features of a Benzo Use Disorder vs Benzo physiologic dependence Tolerance Withdrawal Benzo dependence alone Benzo use disorder Tolerance Withdrawal Loss of control of use Continued use despite social or interpersonal issues related to use Giving up other activities due to use No longer fulfilling major life obligations Consistent use despite acknowledgement of harms Wanting to cut down, but not being able Taking in larger amounts and longer than intended
18 Taper plan: prolonged taper Stabilize patient over 1-2 weeks on a dose of long acting benzos (clonazepam) mostly equivalent to her current prescription for diazepam Care coordinate with her friend to help manage medication and inform you if there are any issues Start very slow taper of clonazepam by 0.25mg per day every 2 weeks Consider inpatient assistance Add propranolol due to patient avoidance of all other meds Taper takes 1 year and is successful
19 Case 3: REAL case Jimmy is a 22 year old man with hx of tobacco use who has been ordering a research benzodiazepine (etizolam) from CA for the last year. Total dose of 20mg per day. He also drinks a 6 pack of beer per day. He has received a DWI due to driving while intoxicated. He has had 2 seizures in the past due to attempting to taper his use on his own. He feels restless, anxious, sweaty, and has vomiting. He would like to get back to work for the parks service as soon as possible. His parents have threatened to kick him out of the house if he does not stop his use.
20 Features of a Benzo Use Disorder vs Benzo physiologic dependence Tolerance Withdrawal Benzo dependence alone Benzo use disorder Tolerance Withdrawal Loss of control of use Continued use despite social or interpersonal issues related to use Giving up other activities due to use No longer fulfilling major life obligations Consistent use despite acknowledgement of harms Wanting to cut down, but not being able Taking in larger amounts and longer than intended
21 Taper plan Inpatient admission for detoxification Start Depakote 250mg TID, continue 3 weeks Schedule Librium mg QID x 1 day and then reduce by 25-50mg per day depending on time in detox Continue PRN Librium as well Work with family on safe discharge plan Advise against working or driving for the next week, minimum Start vistaril, buspar, trazodone to help with symptom relief
22 Alternatives to Benzos for anxiety Gabapentin Prazosin Seroquel Mirtazepine SSRIs Melatonin Vistaril Buspar *List is not in order of preference and not an exhaustive list *Always choose a medication best suited for the specific problem you are attempting to address
23 References Soyka, Treatment of Benzodiazepine Dependence. NEJM 376; 12. March 23, /Opioid-and-Benzodiazepine-Tapering-flow-sheets.pdf
Basics of Benzodiazepine Use Disorder. DATE: March 20, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR
Basics of Benzodiazepine Use Disorder DATE: March 20, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members
More informationBasics of Benzodiazepine Use Disorder. DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR
Basics of Benzodiazepine Use Disorder DATE: June 12, 2018 PRESENTED BY: Melissa B. Weimer, DO, MCR Disclosures Speaker: Melissa Weimer, DO, MCR, has nothing to disclose. Planning Committee: The members
More informationMEDICATION ALGORITHM FOR ANXIETY DISORDERS
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences MEDICATION ALGORITHM FOR ANXIETY DISORDERS RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL PSYCHIATRY UNIVERSITY OF WASHINGTON
More informationWHEN AND HOW TO USE BENZODIAZEPINES IN TREATING ANXIETY: AM I WITHHOLDING TREATMENT IF I DON'T USE BENZODIAZEPINES?
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences WHEN AND HOW TO USE BENZODIAZEPINES IN TREATING ANXIETY: AM I WITHHOLDING TREATMENT IF I DON'T USE BENZODIAZEPINES?
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St.
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners, Albany, NY Assistant Professor of Medicine,
More informationUsing Benzodiazepines in Primary Care
Using Benzodiazepines in Primary Care Spencer A. Tighe MD, FRCPC Saturday, Feb. 16, 2008 Overview Historical context Drug information Indications Side effects Abuse vs. physical dependence Clinical practice
More informationAnxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Anxiety Pharmacology UNIVERSITY OF HAWAI I HILO PRE NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the normal processing of fear vs fear processing
More informationManaging presenting problems with benzodiazepines. By Dr Gideon Felton MRCPsych Consultant Psychiatrist and Clinical Lead
Managing presenting problems with benzodiazepines By Dr Gideon Felton MRCPsych Consultant Psychiatrist and Clinical Lead OUTLINE OF PRESENTATION Why Benzodiazepines (BDZ s) are used Mechanism of Action
More informationBenzodiazepines: Comparative Effectiveness and Strategies for Discontinuation. Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project
Benzodiazepines: Comparative Effectiveness and Strategies for Discontinuation Ann M. Hamer, PharmD, BCPP Rural Oregon Academic Detailing Project This project is funded through a grant from the Pew Charitable
More informationWHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014
WHAT SHOULD WE DO ABOUT BENZODIAZEPINES? Miriam Komaromy, MD Associate Director, Project ECHO August 2014 EPIDEMIOLOGY OF BENZO USE 7-18% of US population uses a benzo for medical purposes each year Average
More informationTreatment of Anxiety (without benzos)
Treatment of Anxiety (without benzos) Alison C. Lynch MD MS Clinical Professor Departments of Psychiatry and Family Medicine University of Iowa Health Care None Disclosures Overview/objectives Review common
More informationStrategies in Managing Opioid and Benzodiazepine Co-Prescribing
Strategies in Managing Opioid and Benzodiazepine Co-Prescribing Scott Endsley, MD Associate Medical Director, Quality Partnership HealthPlan of California October 25, 2016 Audio Instructions To avoid echoes
More informationPractical Tools to Successfully Taper Prescription Opioids. Melissa Weimer, DO, MCR
Practical Tools to Successfully Taper Prescription Opioids Melissa Weimer, DO, MCR Objectives Understand how to calculate morphine equivalents per day Understand the steps necessary to plan a successful
More informationten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment
ten questions you might have about tapering (and room for your own) an informational booklet for opioid pain treatment This booklet was created to help you learn about tapering. You probably have lots
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationMANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER
MANAGING PAIN IN PATIENTS WITH SUBSTANCE USE DISORDER Melissa B. Weimer, DO, MCR Chief of Behavioral Health & Addiction Medicine St. Peter s Health Partners Grand Rounds October 11, 2017 Disclosures One
More informationTreating Anxiety Disorders. Adil Virani, BSc (Pharm), Pharm D, FCSHP
Treating Anxiety Disorders Adil Virani, BSc (Pharm), Pharm D, FCSHP Outline! Michelle s Case! Types of anxiety disorders! Goals of therapy! Treatment options and guidelines! Pharmacological options! Benzodiazepines
More informationCOMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications*
COMMONLY PRESCRIBED PSYCHOTROPIC MEDICATIONS NAME Generic (Trade) DOSAGE KEY CLINICAL INFORMATION Antidepressant Medications* Bupropion (Wellbutrin) Start: IR-100 mg bid X 4d then to 100 mg tid; SR-150
More informationANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN
UW PACC Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN RYAN KIMMEL, MD MEDICAL DIRECTOR HOSPITAL
More information11/1/2010. Psychology 472 Pharmacology of Psychoactive Drugs. Listen to the audio lecture while viewing these slides
Treatment for Anxiety Disorders Benzodiazepines and Other Anxiolytics Psychology 472 Pharmacology of Psychoactive Drugs Listen to the audio lecture while viewing these slides Ethanol Barbiturates and related
More informationSession 2: Mental Health A: Alcohol Dependency: The Pharmacist s Role in Detox and Treatment 1:45pm - 2:45pm
January 20-22, 2012 Des Moines Marrio, 700 Grand Avenue, Des Moines, IA Session 2: Mental Health A: Alcohol Dependency: The Pharmacist s Role in Detox and Treatment 1:45pm - 2:45pm ACPE UAN 107-000-12-015-L01-P
More informationDifficult Conversations
Difficult Conversations D R. L Y D I A A N N E M B A R T H O L O W, D N P, P M H N P, C A R N - AP Skill Building Patient centered Boundaries and self-protection Trauma informed Care 1 Skill Building Trauma
More informationIdentification and Management of Benzodiazepine and Z-drug abuse
CSAM-SCAM Fundamentals Identification and Management of Benzodiazepine and Z-drug abuse Presentation provided by Dr. Mandy Manak MD, ABAM, CSAM, MRO Interior Chemical Dependency Office Disclosures Potential
More informationSCENARIOS IN SUBSTANCE MISUSE. By Dr Gideon Felton Consultant Psychiatrist and Clinical Lead
SCENARIOS IN SUBSTANCE MISUSE By Dr Gideon Felton Consultant Psychiatrist and Clinical Lead ALCOHOL SCENARIOS DON T PRESCRIBE LIBRIUM AS YOU ARE CONTRIBUTING TO A SECOND ADDICTION WITHOUT TREATING THE
More informationOLDER ADULTS & DEPRESCRIBING: TREATMENT
OLDER ADULTS & DEPRESCRIBING: CONTEMPLATION, ASSESSMENT & TREATMENT Jonathan Bertram Faculty/Presenter Disclosure Faculty: Jonathan Bertram Relationships with commercial interests: Grants/Research Support:
More informationVistaril ( hydroxyzine ) is a non-addictive antihistamine medication. This drug is used to relieve the itching caused by allergies and to control the
Vistaril ( hydroxyzine ) is a non-addictive antihistamine medication. This drug is used to relieve the itching caused by allergies and to control the nausea and. wisdom in this exchange. Alprazolam, available
More informationSedatives and Hypnotics. Ahmad Al-Tarifi. Zahra Khalil. Pharmacology. 1 P a g e
Sedatives and Hypnotics Ahmad Al-Tarifi Zahra Khalil 1 P a g e Pharmacology 7 OCD can lead to an anxious behavior and anxiety can be treated with drugs called Sedatives and Hypnotics. What are sedatives?
More informationUSUAL DOSE OF XANAX. Usual Dose Of Xanax
USUAL DOSE OF XANAX Usual Dose Of Xanax Withdrawal what symptoms xanax from Compared valium to xanax.5 Valium vs vs xanax ativan Gocce mg 0 xanax 25 quante Melatonin between and xanax interactions Lb xanax
More informationBenzodiazepines. Benzodiazepines
: History 1950s - Invented by Swiss chemists who identified its sedative effects 1950s 60s - Chlordiazepoxide (Librium) marketed as a safer alternative to barbiturates; along with newer benzodiazepines
More informationAntidepressant Medication Therapy in Primary Care July 25, 2013
New York State Collaborative Care Initiative Antidepressant Medication Therapy in Primary Care July 25, 2013 http://uwaims.org Presenter Building on 25 years of Research and Practice in Integrated Mental
More informationFriend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines
Friend or Foe? Review of the Regulations & Benefits: Risk Profiles of the Benzodiazepines Program Learning Objectives At the conclusion of the activity, participants should be able to: Have a basic understanding
More informationDisclosures. Objectives. Symptoms of fear. The Fifteen Minute Hour: Psychotherapy & Medications for Anxiety Management in Primary Care 4/5/18
Disclosures The Fifteen Minute Hour: Psychotherapy & Medications for Anxiety Management in Primary Care I have nothing to disclose Emma Samelson-Jones, MD Assistant Clinical Professor UCSF Department of
More informationTapering Opioids Best Practices*
Tapering Opioids Best Practices* Chuck Hofmann, MD, MACP 5 th Annual EOCCO Office Staff and Provider Summit September 28, 2017 Disclosure No Conflicts of Interest to report Learning Objectives Understand
More informationAnxiolytic & Hypnotic Drugs. Asst Prof Dr Inam S Arif
Anxiolytic & Hypnotic Drugs Asst Prof Dr Inam S Arif isamalhaj@yahoo.com Anxiolytic & Hpnotic Agents Anxiety: unpleasant state of tension, apprehension or uneasiness, characterised by, tachycardia, sweating,
More informationAtivan cause elevated liver enzymes
Ativan cause elevated liver enzymes The Borg System is 100 % Ativan cause elevated liver enzymes Nov 13, 2013. Benzodiazepines and the Liver. Some are just metabolized by different pathways that are less
More informationFor: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013
For: NEON Primary Healthcare Providers By: Michelle Romero, DO June 2013 This power point is only a guideline for recommendations in the treatment of psychiatric disorders. This is not comprehensive. Please
More informationBOOTS ON THE GROUND CRUCIAL CONVERSATIONS RELATED TO MEDICATION TAPERING
BOOTS ON THE GROUND CRUCIAL CONVERSATIONS RELATED TO MEDICATION TAPERING YOUR SPEAKER Eva Quirion, BSN, MSN, FNP-C, PhD Pain and Recovery Care St. Joseph Internal Medicine 900 Broadway, Building #5 Bangor,
More informationROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS
ROLE OF HEALTH CARE PROVIDERS IN THE MANAGEMENT OF ALCOHOL AND DRUG USE RELATED PROBLEMS Dr. Anita Rao? ASK SCREEN Refer HELP T T Ranganathan Clinical Research Foundation TTK Hospital IV Main Road, Indira
More informationPharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) Declaration of Interests
Pharmacotherapy of Anxiety Disorders (GAD, Panic, & SAD) University of Texas Health Science Center San Antonio Pharmacotherapy Education and Research Center (PERC) 7703 Floyd Curl Drive - MSC 6220 San
More informationPrepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry
Prepared by: Dr. Elizabeth Woodward, University of Toronto Resident in Psychiatry In broad terms, substance use disorders occur when a substance is used in a compulsive manner with a lack of control over
More informationsome things you should know about opioids before starting a prescription an informational booklet for opioid pain treatment
some things you should know about opioids before starting a prescription an informational booklet for opioid pain treatment This booklet was created to help you learn about opioids. You probably have lots
More informationBuprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM. Disclosures
Buprenorphine 2.0: I have my waiver, now what? Dr. Ritu Bhatnagar, M.D., M.P.H. Dr. John Ewing, M.D., FASAM Disclosures Dr. Bhatnagar: no disclosures to report Dr. Ewing: no disclosures to report 1 Our
More informationAnxiety Disorders.
Anxiety Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationDr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging.
David W. Oslin, MD University of Pennsylvania Philadelphia VAMC Dr. Oslin receives grant support from the NIH, VA, and the Pennsylvania Department of Aging. Dr. Oslin is a consultant to the Hazelden Betty
More informationDisclosures. Overview of Workshop. Objectives. Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression
Medical Care of Vulnerable and Underserved Populations: Advanced Cases in Anxiety and Depression Disclosures The speakers have no disclosures. Lisa Ochoa-Frongia, MD Christina Mangurian, MD, MAS L. Elizabeth
More informationBENZODIAZEPINES: WHAT YOU DON T KNOW CAN HURT YOU
BENZODIAZEPINES: WHAT YOU DON T KNOW CAN HURT YOU TABLE OF CONTENTS 4 Benzodiazepine Addiction 8 Xanax Withdrawal Symptoms 11 Professional Help for Benzo Withdrawal is Essential for Success 15 Relapse
More informationMultiple Choice Questions
Multiple Choice Questions 25yo M presents without psychiatric or medical history, with complaint of tremor to the ER. He denies drinking alcohol but his friend at bedside takes you to the side and reports
More informationAnxiolytic, Sedative and Hypnotic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anxiolytic, Sedative and Hypnotic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Anxiolytics: reduce anxiety Sedatives: decrease activity, calming
More informationCHILDHOOD/ADOLESCENT ANXIETY DISORDERS: EVALUATION AND TREATMENT
CHILDHOOD/ADOLESCENT ANXIETY DISORDERS: EVALUATION AND TREATMENT PHILIP L. BAESE, MD ASSISTANT PROFESSOR OF PSYCHIATRY CHIEF, DIVISION OF CHILD AND ADOLESCENT PSYCHIATRY UNIVERSITY OF UTAH, SCHOOL OF MEDICINE
More informationCan klonopin help withdrawal opiates
Can klonopin help withdrawal opiates Search During detox, people can lose large amounts of bodily fluids (and with them important nutrients and electrolytes). There is also a possibility of breathing in
More informationALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH
ALCOHOL USE DISORDER WITHDRAWAL MANAGEMENT AND LONG TERM TREATMENT ANA HOLTEY, MD ADDICTION MEDICINE FELLOW UNIVERSITY OF UTAH HEALTH Prevalence of 12-Month Alcohol Use, High-Risk Drinking, and DSM-IV
More informationSedative / Hypnotics
Sedative / Hypnotics David H. Rubin, MD Executive Director, Massachusetts General Hospital Psychiatry Academy Director of Child and Adolescent Psychiatry Residency Training Massachusetts General Hospital
More informationDRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS
DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DR IÑIGO PEREZ MEDICAL ADVISER, DVLA GENERAL PRACTICE HOT TOPICS LIVERPOOL 4 FEBRUARY 2017 OUTLINE Case Scenarios Fit to fly X Fit to drive Drug driving Epilepsy
More informationDRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS
DRIVING, DVLA, AND ADVISING PATIENTS: TOP TIPS DR IÑIGO PEREZ MEDICAL ADVISER, DVLA GENERAL PRACTICE HOT TOPICS NOTTINGHAM 22 APRIL 2017 OUTLINE Drug driving Epilepsy concessions Fit to drive DRUG DRIVING
More informationAn algorithm for medication in the treatment of Complex PTSD
An algorithm for medication in the treatment of Complex PTSD Andreas Laddis, M.D. aladdis@gmail.com ESTD Conference Bern November 10, 2017 The purpose for the presentation Algorithm for medication: My
More information8/15/17. Managing Psychiatric Conditions in Primary Care Beyond the Basics. Speaker s Biography. Situation
Managing Psychiatric Conditions in Primary Care Beyond the Basics Source: US National Library of Medicine, Images from the History of Medicine Luis Berrios, DNP, MHA, ANP, PMHNP Internal Medicine & Primary
More informationDosage xanax to stop drinking
What Are Xanax Withdrawal Symptoms? Xanax withdrawal symptoms can take hold within hours of the last dose, and they can peak in severity within 1-4 days.. Over time, Xanax may actually influence the production
More informationBenzodiazepines. CRIT program May Alex Walley, MD, MSc Assistant Professor of Medicine Boston University School of Medicine
Benzodiazepines CRIT program May 2010 Alex Walley, MD, MSc Assistant Professor of Medicine Boston University School of Medicine Medical Director, Opioid Treatment Program Boston Public Health Commission
More informationOpioid Use Disorder Treatment: Buprenorphine Treatment Basics
Opioid Use Disorder Treatment: Buprenorphine Treatment Basics Daniel Warren, MD Eastern Oregon Coordinated Care Organization Provider Forum on Chronic Noncancer Pain Management Pendleton, OR February 24,
More informationManaging presenting alcohol users an Introduction to SPECTRUM (CRI) By Dr Gideon Felton MRCPsych Consultant Psychiatrist and Clinical Lead
Managing presenting alcohol users an Introduction to SPECTRUM (CRI) By Dr Gideon Felton MRCPsych Consultant Psychiatrist and Clinical Lead PLAN OF PRESENTATION Assessment of alcohol dependence Psychiatric
More informationThe fact that your asking your doctor for a drug like Valium by name is enough to raise alarms that your just drug seeking. People like...
The fact that your asking your doctor for a drug like Valium by name is enough to raise alarms that your just drug seeking. People like... OP never replied back to this thread, so we can't tell if they're
More informationTreating Pain and Depression
Treating Pain and Depression Without Getting Depressed Joseph P, Arpaia, MD www.jparpaiamd.com More than 50% of patients with chronic pain also have clinically significant depression. Interestingly that
More informationBest Practices in Prescribing Benzodiazepines. Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center
Best Practices in Prescribing Benzodiazepines Michael Carlisle, DO Medical Director University Hospitals Geauga Medical Center Objectives To review current practice guidelines in benzodiazepine prescribing
More informationANTICONVULSANTS IN ALCOHOL WITHDRAWAL TREATMENT: A BETTER WAY?
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences ANTICONVULSANTS IN ALCOHOL WITHDRAWAL TREATMENT: A BETTER WAY? RICHARD RIES MD PROFESSOR OF PSYCHIATRY AND DIRECTOR
More informationCanadian Guideline for Opioids for Chronic Non-Cancer Pain. Speaker Disclosure. Objectives. Canadian Guideline for Opioids for Chronic Non-Cancer Pain
Canadian Guideline for Opioids for Chronic Non-Cancer Pain John Fraser Community Hospital Program New Glasgow November 1, 2017 This speaker has been asked to disclose to the audience any involvement with
More informationAlcohol Use in the Elderly
Substance Use/Abuse in the Geriatric Population Alan L. Schneider, MD DFAPA DABAM Medical Director, Western Region Aetna Behavioral Health Associate Professor of Psychiatry, UCLA School of Medicine Alcohol
More informationTapering off.5 xanax. Tapering off.5 xanax
Tapering off.5 xanax The Borg System is 100 % Tapering off.5 xanax 4-5-2017 How to Withdraw from Alprazolam.. Tapering off (slowly reducing. I was scared to death; nobody explained the process of getting
More informationTapering off ativan.5
Tapering off ativan.5 Search 10-3-2012 Home Q & A Questions Anxiety - Properly tapering. Anxiety - Properly tapering off Ativan?. I have been on.5 mg ativan for about 3 weeks. Ativan Withdrawal and Detox..
More information1/20/2017. Benzodiazepines Overuse. Pharmacist Objectives. Technician Objectives. A Bit of History. Benzodiazepines: Mechanism of Action
Pharmacist Objectives Participants will review the pharmacology of benzodiazepines and be able to identify how various benzodiazepines differ. Benzodiazepines Overuse Steve Jenkusky, MD January 29, 2017
More informationDRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS
DRUGS USED IN THE TREATMENT OF ADDICTION JOSEPH A. TRONCALE, MD FASAM RETREAT PREMIERE ADDICTION TREATMENT CENTERS MAJOR CATEGORIES OF TREATMENTS Detoxification and Post-Acute Withdrawal Maintenance Co-Occurring
More informationAn overview of Medication Assisted Treatment (MAT) and acute pain management on MAT
An overview of Medication Assisted Treatment (MAT) and acute pain management on MAT Goals of Discussion Recognize opioid use disorder (OUD) Discuss the pharmacology of medication assisted treatments (MAT)
More informationMedications For Alcohol Use Disorder
Medications For Alcohol Use Disorder PRESENTED BY: Alann Weissman-Ward, MD, Addiction Medicine fellow June 19, 2018 DISCLOSURES Speaker: Alann Weissman-Ward, MD, has nothing to disclose. Planning Committee:
More informationManaging Pain in the Patient with Opioid Use Disorder: Inpatient Management. Melissa Weimer, DO, MCR Oregon Health & Science University
Managing Pain in the Patient with Opioid Use Disorder: Inpatient Management Melissa Weimer, DO, MCR Oregon Health & Science University 1 Educational Objectives At the conclusion of this activity participants
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationAssessing and Treating Cooccurring
Assessing and Treating Cooccurring Mental Illness and SUD Joshua Boverman M.D. Medical Director, Wallowa Valley Center for Wellness Consulting Psychiatrist, Winding Waters Clinic Affiliate Assistant Professor
More informationPsychoactive Medications. Alya Reeve, MD Carla Fedor, RN, CDDN Continuum of Care Project
Psychoactive Medications Alya Reeve, MD Carla Fedor, RN, CDDN Continuum of Care Project PSYCHOACTIVE MEDICATIONS Definition: Any medication which has the capability to alter mood, anxiety, behavior or
More informationMental Health Nursing: Anxiety Disorders. By Mary B. Knutson, RN, MS, FCP
Mental Health Nursing: Anxiety Disorders By Mary B. Knutson, RN, MS, FCP A Definition of Anxiety Diffuse apprehension that is vague in nature and associated with feelings of uncertainty and helplessness
More informationUniversal Precautions and Opioid Risk. Assessment. Questions: How often do you screen your patients for risk of misuse when prescribing opioids?
Learning objectives 1. Identify the contribution of psychosocial and spiritual factors to pain 2. Incorporate strategies for identifying and mitigating opioid misuse 3. Incorporate non-pharmaceutical modalities
More informationMucky Meds: A (practical) approach the nightmare med list. Michelle Gibson, MD, CCFP (COE), FCFP and Erin Beattie, MD, CCFP
Mucky Meds: A (practical) approach the nightmare med list Michelle Gibson, MD, CCFP (COE), FCFP and Erin Beattie, MD, CCFP Faculty/Presenter Disclosure Faculty: Michelle Gibson Relationships with financial
More informationSafe Alprazolam Prescribing and Benzodiazepine Monitoring Program
Clinical Track Safe Alprazolam Prescribing and Benzodiazepine Monitoring Program Brian S. Taylor, MD, Medical Director, Adult Services and ADP, Ventura County (California) Behavioral Health Celia Woods,
More informationWhat You Need to Know About Benzodiazepines & Other Anxiety Drugs
Anxiety Medication What You Need to Know About Benzodiazepines & Other Anxiety Drugs When you re overwhelmed by heartpounding panic, paralyzed by fear, or exhausted from yet another sleepless night spent
More informationPsychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan
Psychopharmacology in the Emergency Room Michael D. Jibson, M.D., Ph.D. Associate Professor of Psychiatry University of Michigan Pretest 1. Appropriate target symptoms for emergency room medication treatment
More informationPOLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences POLYSUBSTANCE USE IN THE TREATMENT OF OPIOID USE DISORDER WITH BUPRENORPHINE MARK DUNCAN, MD November 8, 2018 SPEAKER
More information7/7/2016 Journal of the American Medical Association,
1 2 Journal of the American Medical Association, 2008 3 The Clinical Trial 152 Adolescents and Young Adults (Age 15 to 21) randomly assigned to either; 1. 2 weeks of Buprenorphine detox 2. 12 weeks of
More informationManagement of high risk MMT patients. Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013
Management of high risk MMT patients Meldon Kahan MD Methadone Prescribers Conference Toronto, Nov 15, 2013 CFPC CoI Templates: Slide 1 Faculty Disclosure Faculty: Meldon Kahan Relationships with commercial
More informationCommon Psychiatric Conditions in Children. Steven Klamerus, M.D. Child and Adolescent Psychiatrist Marquette General Hospital
Common Psychiatric Conditions in Children Steven Klamerus, M.D. Child and Adolescent Psychiatrist Marquette General Hospital (Child) Psychiatry is different Phenomenological diagnoses verses pathologic
More information1/26/2016. These are my own thoughts! Safe Workplace Safe Workforce Proven benefits of Stay At Work / Return To Work Process (SAW/RTW)
Dr. Paul A. Farnan farnan@mail.ubc.ca HealthQuest Occupational Health Corporation Alliance Medical Monitoring I have no financial interests or affiliation with any pharmaceutical industry or manufacturer
More informationInsomnia: Updates in Medical Management. Michael Newnam M.D.
Insomnia: Updates in Medical Management Michael Newnam M.D. Sleep Neurobiology Delicate balance of excitatory and inhibitory neurotransmitters that control the switch between wakefulness and sleep Circadian
More informationPsychiatric Illness. In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis
Psychiatric Illness In the medical arena psychiatry is a fairly recent field A challenging field Numerous diagnosis 12,000,000 children infants through 18 y/o nation wide 5,000,000 suffer severely Serious
More informationPharmacological Treatment of Anxiety & Depressive Disorders
Pharmacological Treatment of Anxiety & Depressive Disorders Dr Gary Jackson (MB BCh FRCPsych) Consultant Psychiatrist The Priory Hospital Chelmsford Wellesley Hospital Southend-on-Sea Medical Secretary:
More informationAcute General Medical and Surgical Admission:
Acute General Medical and Surgical Admission: Managing Substance Use Disorders in Patients Who are Severely Ill Scott Grantham, MD Executive Director, Behavioral Health Saint Francis Health System By the
More informationTreatment of Substance Use Disorders in the Real World. Jessica M. Peirce, Ph.D. Johns Hopkins University School of Medicine
Treatment of Substance Use Disorders in the Real World Jessica M. Peirce, Ph.D. Johns Hopkins University School of Medicine Objectives identify the core components of the most common substance use disorder
More informationMeds and Falls: Keep in Step with your Meds
Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu
More informationTreatment of Anxiety Disorders Controlled Substance Workshop. Shonda Phelon MSN, FNP-BC, APMHNP-BC MNA Convention 2011
Treatment of Anxiety Disorders Controlled Substance Workshop Shonda Phelon MSN, FNP-BC, APMHNP-BC MNA Convention 2011 Term used to describe both symptoms and disorders Occurs normally Very common symptom
More informationPROCEDURE REF NO SABP/EXECUTIVE BOARD/0017
PROCEDURE REF NO SABP/EXECUTIVE BOARD/0017 NAME OF GUIDELINE REASON FOR GUIDELINE WHAT THE GUIDELINE WILL ACHIEVE? WHO NEEDS TO KNOW ABOUT IT? Medicines Guideline: Hypnotic Medication Compliance with NICE
More informationDoreen Wan-Chow-Wah, MD, FRCPC Assistant Professor, Division of Geriatric Medicine, Department of Medicine McGill University Health Center Associate
Doreen Wan-Chow-Wah, MD, FRCPC Assistant Professor, Division of Geriatric Medicine, Department of Medicine McGill University Health Center Associate member, Department of Oncology McGill University Medical
More informationDISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea
DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,
More informationNORTHWEST AIDS EDUCATION AND TRAINING CENTER. Opioid Use Disorders. Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Opioid Use Disorders Joseph Merrill M.D., M.P.H. University of Washington April 10, 2014 Opioid Use Disorders Importance of opioid use disorders Screening and
More informationSoma (carisoprodol), Soma Compound (carisoprodol and aspirin), Soma Compound w/ Codeine (carisoprodol and aspirin and codeine)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.07 Subject: Page: 1 of 7 Last Review Date: September 15, 2016 Description (carisoprodol), Compound
More information